Open Access Open Access  Restricted Access Subscription or Fee Access

Key characteristics and habits of the recreational opioid user

Anna Schinas, MSc, Shein Nanji, BSc, Kira Vorobej, MSc, Catherine Mills, MSc, Dawn Govier, BSc, Beatrice Setnik, PhD

Abstract


Objective: To identify key characteristics and habits of recreational opioid users.

Design: The data were compiled from volunteers who participated in clinical studies at a contract research organization in Toronto, Ontario, Canada.

Interventions: Data were collected from 5,018 male and female recreational opioid users via telephone and face-to-face screening interviews. Five recreational opioid users participated in a live interview broadcast on the internet.

Main outcome measures: Demographic data, recreational drug use history, routes of recreational drug administration, alcohol use, and smoking status. A subset of the demographic information and recreational drug use history was summarized separately using data collected between 2013 and 2016 from 114 recreational opioid users who were not dependent on opioids. Interview excerpts were included from five recreational opioid users who described their real-world experiences with drug abuse, including the impact of abuse-deterrent opioid formulations on their drug abuse behavior.

Results: The preferred route of administration of opioids was oral (52 percent), followed by intranasal (36 percent), intravenous (10 percent), and buccal (chewing on a patch; 2 percent). Other substances used included nicotine, alcohol, and non-opioid psychoactive drugs (primarily cannabis). Oxycodone was the most frequently reported opioid of abuse.

Conclusions: Recreational opioid users have distinct drug-related behaviors and preferences. Monitoring current trends and examining these behaviors is an important component to understand the potential safety risks associated with recreational opioid use.


Keywords


opioid, recreational drug user, human abuse potential, drug abuse history, abuse-deterrent formulation

Full Text:

PDF

References


National Advisory Committee on Prescription Drug Misuse: First Do No Harm: Responding to Canada’s Prescription Drug Crisis. Ottawa, ON: Canadian Centre on Substance Abuse, 2013. Available at http://www.ccsa.ca/Resource%20Library/Canada-Strategy-Prescription-Drug-Misuse-Report-en.pdf. Accessed March 1, 2017.

Parliament of Canada: The federal role in addressing prescription drug abuse in Canada. HESA Committee Report. Available at http://www.ourcommons.ca/DocumentViewer/en/41-2/HESA/report-2. Accessed December 14, 2018.

Substance Abuse and Mental Health Services Administration: Prescription drug misuse and abuse. Available at https://www.samhsa.gov/prescription-drug-misuse-abuse. Accessed March 1, 2017.

Substance Abuse and Mental Health Services Administration: Prescription drug use and misuse in the United States: Results from the 2015 National Survey on Drug Use and Health. Available at https://www.samhsa.gov/data/sites/default/files/NSDUHFFR2-2015/NSDUH-FFR2-2015.htm. Accessed March 1, 2017.

World Health Organization: Lexicon of alcohol and drug terms. Available at http://www.who.int/substance_abuse/terminology/who_lexicon/en/. Accessed June 12, 2018.

Government of Canada: Canadian Tobacco Alcohol and Drugs (CTADS): 2017 summary. Available at https://www.canada.ca/en/health-canada/services/canadian-tobacco-alcoholdrugs-survey/2017-summary.html. Accessed December 12, 2018.

Schoedel KA, Rolleri RL, Faulknor JY, et al.: Assessing subjective and physiologic effects following intranasal administration of a new formulation of immediate release oxycodone HCl (Oxecta™) tablets in nondependent recreational opioid users. J Opioid Manag. 2012; 8(5): 315-327.

Setnik B, Roland CL, Cleveland JM, et al.: The abuse potential of Remoxy®, an extended-release formulation of oxycodone, compared with immediate- and extended-release oxycodone. Pain Med. 2011; 12(4): 618-631.

United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry: Assessment of Abuse Potential of Drugs. Silver Spring, MD: FDA, 2017. Available at https://www.fda.gov/media/116739/download. Accessed July 9, 2019.

NIH: How does NIDA use the terms drug abuse and addiction? National Institute on Drug Abuse Media Guide: The Science of Drug Use and Addiction: The Basics. Bethesda, MD: NIH, 2016. Available at https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/mediaguide_11_16.pdf. Accessed October 24, 2017.

National Institute on Drug Abuse: Misuse of prescription drugs summary. Available at https://www.drugabuse.gov/publications/misuse-prescription-drugs/overview. Accessed December 14, 2018.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Text Revision. Washington, DC: American Psychiatric Association, 2000.

American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association, 2013.

Government of Canada, Health Canada: Guidance Document: Tamper-Resistance Formulations of Opioid Drug Products. Ottawa, ON, Canada: Minister of Public Works and Government Services Canada, 2016.

United States Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for Industry: Abuse-Deterrent Opioids- Evaluation and Labeling. Silver Spring, MD: FDA, 2015. Available at https://www.fda.gov/media/84819/download. Accessed July 9, 2019.

Hopyan T, Geoffroy P, Hirata Y, et al.: Redefining the recreational drug user population in human abuse potential studies. J Clin Pharmacol. 2016; 56(6): 657-659.

Jordan CJ, Andersen SL: Sensitive periods of substance abuse: Early risk for the transition to dependence. Dev Cogn Neurosci. 2017; 25: 29-44.

Volkow ND, Morales M: The brain on drugs: From reward to addiction. Cell. 2015; 162(4): 712-725.

DRUGSCAN® and INC Research Toronto, Inc.: Untangling methods to tamper with opioid formulations: Perspectives from the benchtop to the real world [Webinar]. 2017. Available at http://drugscan.com/Contents/Resources/CATonewebinars.aspx. Accessed March 14, 2019.

Jones CM, McAninch JK: Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015; 49(4): 493-501.

Jones CM, Paulozzi LJ, Mack KA: Alcohol involvement in opioid pain reliever and benzodiazepine drug abuse-related emergency department visits and drug-related deaths—United States, 2010. MMWR Morb Mortal Wkly Rep. 2014; 63(40): 881-885.

Fischer B, Russell C, Murphy Y, et al.: Prescription opioids, abuse and public health in Canada: Is fentanyl the new centre of the opioid crisis? Pharmacoepidemiol Drug Saf. 2015; 24(12): 1334-1336.

Carroll JJ, Green TC, Noonan RK: Evidence-Based Strategies for Preventing Opioid Overdose: What’s Working in the United States: An Introduction for Public Heath, Law Enforcement, Local Organizations, and Others Striving to Serve Their Community. Atlanta, GA: Centers for Disease Control and Prevention, National Center for Injury Prevention and Control, 2018. Available at https://www.cdc.gov/drugoverdose/pdf/pubs/2018-evidence-based-strategies.pdf. Accessed December 13, 2018.

Geoffroy P, Hopyan T, Setnik B: Clinical challenges in the abuse potential assessment of CNS-active drugs, investigator perspectives with a special commentary from a study volunteer. Poster #20 presented at: The International Conference on Opioids, June 5, 2016; Boston, MA

Vietri J, Joshi AV, Barsdorf AI, et al.: Prescription opioid abuse and tampering in the United States: Results of a self-report survey. Pain Med. 2014; 15: 2064-2074.

Gasior M, Bond M, Malamut R: Routes of abuse of prescription opioid analgesics: A review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med. 2016; 128(1): 85-96.

Butler SF, Black RA, Fleming AB: Relative abuse of crush-resistant prescription opioid tablets via alternative oral modes of administration. Pain Med. 2018; 19: 1613-1627.

Ellis MS, Cicero TJ, Dart RC, et al.: Understanding multi-pill ingestion of prescription opioids: Prevalence, characteristics, and motivation. Pharmacoepidemiol Drug Saf. 2019; 28: 117-121.

Setnik B, Roland CL, Goli V, et al.: Self-reports of prescription opioid abuse and diversion among recreational opioid users in a Canadian and a United States city. J Opioid Manag. 2015; 11(6): 463-473.

McCabe SE, Teter CJ, Boyd CJ, et al.: Nonmedical use of prescription opioids among U.S. college students: Prevalence and correlates from a national survey. Addict Behav. 2005; 30(4): 789-805.

Lord S, Downs G, Furtaw P, et al.: Nonmedical use of prescription opioids and stimulants among student pharmacists. J Am Pharm Assoc. 2009; 49(4): 519-528.

Government of Canada, Minister of Justice: Bill C-45. An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts. Assented June 21, 2018. Available at http://www.parl.ca/DocumentViewer/en/42-1/bill/C-45/royal-assent. Accessed December 12, 2018.

Hall W, Lynskey M: Evaluating the public health impacts of legalizing recreational cannabis use in the United States. Addiction. 2016; 111(10): 1764-1773.

Volkow ND, Swanson JM, Evins AE, et al.: Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: A review. JAMA Psychiatry. 2016; 73(3): 292-297.

Katz N, Dart RC, Bailey E, et al.: Tampering with prescription opioids: Nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011; 37(4): 205-217.

Hays LR: A profile of oxycontin addiction. J Addict Dis. 2004; 23(4): 1-9.

Young AM, Havens JR, Leukefeld CG: Route of administration for illicit prescription opioids: A comparison of rural and urban drug users. Harm Reduct J. 2010; 7: 24.

Coplan PM, Kale H, Sandstrom L, et al.: Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013; 22(12): 1274-1282.

Cicero TJ, Ellis MS: Abuse-deterrent formulations and the prescription opioid abuse epidemic in the United States: Lessons learned from oxycontin. JAMA Psychiatry. 2015; 72(5): 424-430.

Food and Drug Administration, Center for Drug Evaluation and Research: Summary Minutes of the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee Joint Meeting. Silver Spring, MD: FDA, 2017. Available at https://www.fda.gov/media/104174/download. Accessed July 9, 2019.

Lammle B: Opana ER-induced thrombotic microangiopathy. Blood. 2017; 129(7): 808-809.

Hunt R, Yalamanoglu A, Tumlin J, et al.: A mechanistic investigation of thrombotic microangiopathy associated with IV abuse of Opana ER. Blood. 2017; 129(7): 896-905.

Institute for Clinical and Economic Review (ICER): Abuse-deterrent formulations of opioids: Effectiveness and value. Final Evidence Report Prepared for the New England Comparative Effectiveness Public Advisory Council. Boston, MA: ICER, 2017. Available at https://icer-review.org/wp-content/uploads/2016/08/NECEPAC_ADF_Final_Report_08_08_17.pdf. Accessed March 14, 2019.

Tufts Center for the Study of Drug Development: Abuse-deterrent opioid development and uptake are tied to efficacy and regulatory/payer policies. Impact report summary. 2017; 19(4). Available at https://csdd.tufts.edu/impact-reports. Accessed March 15, 2019.

Thomas K, Ornstein C: Amid opioid crisis, insurers restrict pricey, less addictive painkillers. Joint publication by ProPublica and The New York Times. September 17, 2017. Available at https://www.propublica.org/article/insurers-limitcoverage-of-pricey-less-addictive-painkillers; https://www.nytimes.com/2017/09/17/health/opioid-painkillers-insurancecompanies.html. Accessed March 15, 2019.

Schatman ME, Webster LR: The health insurance industry: Perpetuating the opioid crisis through policies of cost-containment and profitability. J Pain Res. 2015; 8: 153-158.

Raffa RB, Pergolizzi JV, Muniz E, et al.: Designing opioids that deter abuse. Pain Res Treat. 2012; 2012: 1-10.

Coplan PM, Chilcoat HD, Butler SF, et al.: The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016; 100(3): 275-286.

United States Food and Drug Administration: CDER conversation: Measuring the impact of opioid analgesic formulations with properties designed to deter abuse in the real world. Available at https://www.fda.gov/Drugs/NewsEvents/ucm579817.htm. Accessed June 12, 2018.

Secora AM, Dormitzer CM, Staffa JA, et al.: Measures to quantify the abuse of prescription opioids: A review of data sources and metrics. Pharmacoepidemiol Drug Saf. 2014; 23: 1227-1237.

Kibbe AH, Franko TS, Shah VM: Oxycodone hydrochloride immediate-release analgesic for managing severe pain: Abuse-deterrent formulations. Ther Clin Risk Manag. 2018; 14: 779-782.

Pascali JP, Fais P, Vaiano F, et al.: Internet pseudoscience: Testing opioid containing formulations with tampering potential. J Pharm Biomed Anal. 2018; 153: 16-21.

McNaughton EC, Coplan PM, Black RA, et al.: Monitoring of internet forums to evaluate reactions to the introduction of reformulated OxyContin to deter abuse. J Med Internet Res. 2014; 16(5): e119.

Throckmorton DC, Gottlieb S, Woodcock J: The FDA and the Next Wave of Drug Abuse—Proactive pharmacovigilance. N Engl J Med. 2018; 379: 205-207.




DOI: https://doi.org/10.5055/jom.2019.0542

Refbacks

  • There are currently no refbacks.